FMP
Seelos Therapeutics, Inc.
SEEL
NASDAQ
Inactive Equity
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
0.37 USD
0 (0%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-52.6M
-76.48M
-114.41M
-170.3M
-230.2M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
-54.4M
-80.62M
-118.98M
-172.75M
-232.85M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
1.81M
4.14M
4.58M
2.45M
2.65M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
168.56M
476.3M
395.65M
583.39M
420.67M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
2.96M
2.95M
3.06M
2.94M
4.92M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
-
-
-
-
-
-
-
-
-
-
100
100
100
100
100
100
100
100
100
3.43M
2.35M
3.73M
5.36M
2.58M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
-6.54M
-2.39M
-2.34M
-2.27M
-5.66M
-
-
-
-
-
100
100
100
100
100
-
-
-
-
10.14
66.57M
4.42
4.42
75.87M
675.02M
750.89M
10.1
89.9
9.48
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
-
-
-
-
-
-
-
-
-
-
-52.6M
-76.48M
-114.41M
-170.3M
-230.2M
-
-
-
-
-
-54.4M
-80.62M
-118.98M
-172.75M
-232.85M
-
-
-
-
-
-0.19
-0.19
-0.19
-0.19
-0.19
-0.19
-0.19
-0.19
-0.19
-0.19
-54.4M
-80.62M
-118.98M
-173.04M
-233.29M
-
-
-
-
-
1.81M
4.14M
4.58M
2.45M
2.65M
-
-
-
-
-
2.96M
2.95M
3.06M
2.94M
4.92M
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3.43M
2.35M
3.73M
5.36M
2.58M
-
-
-
-
-
-6.54M
-2.39M
-2.34M
-2.27M
-5.66M
-
-
-
-
-
-58.66M
-79.94M
-115.47M
-171.11M
-241.07M
2.34M
-
-
-
-
9.48
9.48
9.48
9.48
9.48
2.14M
0
0
0
0
2.14M
9.48
0
0
0
2.14M
1.41M
728.99k
66.57M
0.01
0.01095076 -924.963%